Table 4.
Results after structured assessment of patients with interstitial lung disease after infection with SARS-CoV-2
| Structured Assessment | Value |
|---|---|
| Resting SpO2, % | 95.5 ± 3 |
| MRC dyspnea score, median (IQR) | |
| Before COVID-19 | 1.0 (0–3) |
| After COVID-19 | 3.00 (1–5) |
| 6MWT distance, m | 291.2 ± 153.2 |
| 6MWT, % predicted | 54.9 ± 25.0 |
| 6MWT min SpO2 | 90.0 ± 6 |
| Lung function | |
| FEV1, L | 2.4 ± 0.7 |
| FEV1, % | 86.0 ± 13.7 |
| FVC, L | 3.2 ± 1.0 |
| FVC, % | 91.9 ± 16.0 |
| FEV1/FVC, %, median (IQR) | 77.8 (73.2–82.4) |
| TlCO, SI | 5.6 ± 2.2 |
| TlCO, % | 60.6 ± 24.9 |
| KCO, TlCO/L | 1.3 ± 0.3 |
| KCO, % | 88.0 ± 87.6–88.15 |
Definition of abbreviations: 6MWT = 6-minute walk test; COVID-19 = coronavirus disease; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; IQR = interquartile range; KCO = transfer coefficient; MRC = Medical Research Council; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SI = International System of Units; SpO2 = oxygen saturation as measured by pulse oximetry; TlCO = transfer factor of the lung for carbon monoxide.
Data are presented as mean ± standard deviation unless otherwise stated.